法托他汀通过靶向SCAP/SREBP通路促进铁死亡及抑制ARID1A缺失型非小细胞肺癌

陈鑫鸿, 张雪, 刘婷, 张淑敏, 马雨鹏, 来佳辉, 章子晗, 池永斌

Fatostatin targets SCAP/SREBP pathway to inhibit ARID1A-deficient non-small cell lung cancer by promoting ferroptosis

Chen Xinhong, Zhang Xue, Liu Ting, Zhang Shumin, Ma Yupeng, Lai Jiahui, Zhang Zihan, Chi Yongbin

图2 ARID1A缺失对NSCLC细胞脂质、胆固醇合成及HSP90B1表达的影响 Note： A. GSEA of the cholesterol homeostasis and fatty acid metabolism pathways. B/C. Neutral lipid droplet accumulation by Oil Red O staining (B) and quantification (C) in the WT and KO groups. D. Comparison of TCHO levels between the WT and KO groups. E. Comparison of TG levels between the WT and KO groups. F. Box plots of the HSP90B1 and INSIG1 mRNA levels from transcriptome sequencing data. G. Western blotting analysis of SREBP1, SREBP2, HSP90B1, and INSIG1 expression in the WT and KO groups. H. Densitometric quantification of SREBP1, SREBP2, and HSP90B1 protein levels. I/J. Lipid droplet accumulation in ARID1A-KO cells after 17-AAG treatment by Oil Red O staining (I) and quantification (J). K/L. TCHO (K) and TG (L) levels in ARID1A-KO cells after 17-AAG treatment. M/N. Western blotting analysis of SREBP1/2 expression in ARID1A-KO cells after 17-AAG treatment (M) and densitometric quantification (N).

Fig 2 Effects of ARID1Aloss on lipid and cholesterol synthesis and HSP90B1 expression in NSCLC cells